Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shenzhen Builds Up R&D Platform For New Combination Drugs

This article was originally published in PharmAsia News

Executive Summary

Shenzhen National Biomedical Industry Base recently released its key R&D results at China Hi-Tech Fair. Last March, Shenzhen Ausa Pharmed Co., which has been appointed the new combination drug research center for the biomedical base, received Class I new drug certification from China's State FDA for its enalapril maleate and folic acid tablet. This represents the only new drug with intellectual property rights to obtain such certification in the cardiovascular field in the past three years. Experts observe that innovative drug combination, complemented with expansion of drug indications, may form an effective approach that suits China's situation and helps the nation catch up in the global innovation competition. (Click here for more - Chinese Language)

You may also be interested in...

Lilly Signs Deals With Dexcom, Glooko, myDiabby, Roche For Diabetes Management Solutions

Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.

Three IPOs, Three SPAC Mergers, But One Company Opted Out

Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.

Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts